Kezar Life Sciences, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: South San Francisco CA United States (2015)

Organization Overview

First Clinical Trial
2018
NCT03393013
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Kezar | Kezar Life Sciences, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

Zetomipzomib (6 trials)

Drugs in Phase 1 Trials (1)

kzr-261 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 2)

Anemia, Hemolytic (Phase 2)

Anemia, Hemolytic, Autoimmune (Phase 2)

Dermatomyositis (Phase 2)

Hemolysis (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lupus Nephritis (Phase 2)

Nephritis (Phase 2)

Polymyositis (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Thrombocytopenia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 2